MedTrace Logo

Poplar-type Propolis Dry Extract ESIT12 : Nutrikinetic and Bioavailability Studies

NCT06062511 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-12-08

No results posted yet for this study

Summary

The aim of this study is to investigate phenolic compounds from ESIT12, a poplar-type propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and metabolic profile over 48h by means of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). The study follows a cross-over, double-blind, randomized and placebo control design on 10 healthy subjects.

Conditions

  • Nutrition, Healthy

Interventions

DIETARY_SUPPLEMENT

ESIT12 D

ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12

DIETARY_SUPPLEMENT

ESIT12 4D

ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12

DIETARY_SUPPLEMENT

Placebo

Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    collaborator OTHER

  • Fytexia

    lead INDUSTRY

Principal Investigators

  • Pedro E. Alcaraz, PhD · UCAM

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-22
Primary Completion
2023-10-10
Completion
2023-10-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06062511 on ClinicalTrials.gov